Bioiberica Joins Forces with Vall Companys to Invest €25 Million in Manufacturing Heparin

A strategic alliance between Bioibérica and Vall Companys to manufacture heparin for €25 million. The new company, called Biovall Heparin Science, will produce heparin through the extraction of the porcine intestinal mucosa.

The company will be based in Mercazaragoza and will create twenty new jobs. In addition, it will expand the facilities of International Casing Products (ICP), a subsidiary of Valls Company in the same industrial estate. The new plant will be finished in 2025.

Bioiberica is a company that produces the active ingredient heparin. 20% of this compound that is administered in the world comes from Spanish territory and 40% of that consumed in Europe and the United States is produced in Bioiberica.

If you want to find more details about the alliance between Bioiberica and Vall Companys and to read the most important business news of the day, download for free the Born2Invest mobile app.

Bioiberica administers 20% heparin for everyone

The general director of Valls Company, Albert Morera, explained that ” the pig sector has always been characterized by a very high level of circular economy, and with this project, we demonstrate it again by putting the company at the service of society with an essential medicine for human health.”

“A project where we consolidate productive excellence throughout our value chain in Spain in favor of health and innovation” highlighted Luis Solera, CEO of Bioiberica.

According to the latest public financial data of the Catalan company in 2018, it earned €34.2 million in 2018, more than double compared to 2017, when it closed the year with a profit of €15.8 million.

The group attributed these results mainly to the evolution of sales of this injectable coagulant, used to prevent the formation of clots in catheters. Its heparin division generated sales of €149.7 million in 2018, 62.2% more compared to 2017. In fact, these products account for 55% of the company’s total turnover, according to the annual accounts of 2018, which this newspaper has been able to access.

 The Spanish market also grew but at a slower pace. Sales in the country increased by 16.4% in 2018, up to €75.2 million, while the increase in the rest of the world was 3.6%, with €51.3 million.

__

(Featured image by stevepb via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.